Daratumumab Infusion Acceleration
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2019.
- 22 Feb 2017 Status changed from not yet recruiting to recruiting.